GlassScriptPhysician profile
James Douglas Harbin
NPI 1538193016
$536.39
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.08 · 2020: $42.09 · 2023: $74.82 · 2024: $218 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $89.94 | 2019-2025 | Wegovy |
| Organon LLC | $77.46 | 2024-2025 | Nexplanon |
| Lilly USA, LLC | $60.97 | 2024-2025 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $48.56 | 2024-2025 | Veozah |
| Abbvie INC. | $41.98 | 2020-2024 | |
| Pfizer INC. | $29.51 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.26 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $23.70 | 2023 | |
| Coopersurgical, INC. | $20.95 | 2025 | Endosee |
| Exeltis, USA INC. | $20.57 | 2024 | Slynd |
| Baxter Healthcare | $20.17 | 2024 | Perclot |
| Hologic Sales and Service, LLC | $19.88 | 2025 | Thinprep 2000 Processor, Aptima |
| Biogen, INC. | $19.47 | 2025 | Zurzuvae |
| Avanos Medical | $18.90 | 2023 | On-Q* Pump and Accessories |
| Dexcom, INC. | $17.07 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.